Clinical Trial: A Multicenter, Open-label, Single-arm Phase I Clinical Trial on the Safety and Tolerability of Nachiotaxel Injection in the Treatment of Autoimmune Hemolytic Anemia That Has Failed at Least Three Lines of Treatment

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07091370) titled 'A Multicenter, Open-label, Single-arm Phase I Clinical Trial on the Safety and Tolerability of Nachiotaxel Injection in the Treatment of Autoimmune Hemolytic Anemia That Has Failed at Least Three Lines of Treatment' on July 21.

Brief Summary: Main purpose:

To evaluate the safety and tolerability of nkiolabel injection in the treatment of autoimmune hemolytic anemia that has failed at least three lines of treatment.

Determine the recommended phase II dose (RP2D) of nkiolomab in subjects with autoimmune hemolytic anemia who have failed at least three lines of treatment.

Secondary purpose:

To evaluate the efficacy of nkiolabel inje...